Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea

BACKGROUND: Anti-PD1 inhibitors have been approved for the treatment of recurrent or metastatic head and neck cancer (HNC), as a result of Global Phase III trials. However, the clinical outcomes of immune checkpoint inhibitors in patients who are not eligible for clinical trials or have various medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyera, Kwon, Minsuk, Kim, Binnari, Jung, Hyun Ae, Sun, Jong-Mu, Lee, Se-Hoon, Park, Keunchil, Ahn, Myung-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405432/
https://www.ncbi.nlm.nih.gov/pubmed/32758163
http://dx.doi.org/10.1186/s12885-020-07214-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405432/
https://www.ncbi.nlm.nih.gov/pubmed/32758163
http://dx.doi.org/10.1186/s12885-020-07214-4

Ejemplares similares